+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Lysosomal Storage Diseases Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • PDF Icon

    Report

  • 167 Pages
  • March 2024
  • Region: Global
  • Fairfield Market Research
  • ID: 5947366
Description Jump to:
As the prevalence of lysosomal storage disorders continues to rise globally, the market for therapeutics targeting these rare genetic metabolic diseases is poised for substantial growth during 2024-2031. A comprehensive analysis by the publisher, based on current market dynamics, reveals compelling insights into the factors propelling this growth and the evolving landscape of treatment modalities.

Rising Awareness and Financial Incentives Drive Market Expansion

The surge in diagnosis rates, bolstered by heightened awareness initiatives, coupled with financial incentives incentivizing orphan drug development, is the primary catalyst fueling the expansion of the global lysosomal storage disorders therapeutics market. With pharmaceutical companies intensifying their focus on research and development for rare diseases, the market is witnessing a remarkable uptick in demand, facilitated by faster market access and premium product pricing.

Challenges and Opportunities

While the market presents significant growth opportunities, challenges such as disease heterogeneity leading to underdiagnoses, limited treatment options, and high treatment costs remain formidable barriers. However, the advent of innovative therapies targeting neuropathic pain management and overcoming immune responses promises to reshape the future landscape of lysosomal storage disorders therapeutics, offering renewed hope for patients and healthcare providers alike.

Segment Analysis: Unveiling Market Dynamics

The market segmentation based on indication, type of therapy, and end-user provides valuable insights into the prevailing trends and growth trajectories within the lysosomal storage disorders therapeutics market. Gaucher's Diseases emerges as the dominant indication segment, with Fabry Diseases following closely, reflecting substantial growth potential. Enzyme Replacement Therapy (ERT) leads the therapeutic landscape, accounting for a significant revenue share, while Stem Cell Therapy shows promising growth prospects.

Regional Insights: Europe Leads the Charge

Europe asserts its dominance as the leading market for lysosomal storage disorders therapeutics, with a projected CAGR of 10.2% over the forecast period, driven by robust healthcare infrastructure and favorable regulatory frameworks. North America trails closely behind, poised to capture substantial market share, while Asia Pacific presents lucrative opportunities with a notable absolute $ opportunity.

Key Players Driving Innovation

Leading players such as Shire PLC, Pfizer, Inc., and Sanofi are at the forefront of driving innovation in lysosomal storage disorders therapeutics. Through focused R&D initiatives and strategic collaborations, these market giants aim to develop groundbreaking treatments, further solidifying their market presence and contributing to the advancement of rare disease therapeutics globally.

Market Segmentation:

By Therapy

  • Enzyme Replacement Therapy
  • Stem-cell Therapy
  • Substrate Reduction Therapy
  • Others

By Indication

  • Gaucher's Disease
  • Fabry Disease
  • Pompe’s Syndrome
  • Mucopolysaccharidosis
  • Others

By End User

  • Hospitals
  • Clinics

By Region

  • North America
  • Latin America
  • Europe
  • Asia-Pacific (APAC)
  • Middle East & Africa (MEA)


This product will be delivered within 1-3 business days.

Table of Contents

1. Executive Summary
1.1. Global Lysosomal Storage Diseases Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2023
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter’s Five Forces Analysis
2.5. COVID-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. PESTLE Analysis
3. Global Lysosomal Storage Diseases Market Outlook, 2018 - 2031
3.1. Global Lysosomal Storage Diseases Market Outlook, by Therapy, Value (US$ Bn), 2018 - 2031
3.1.1. Key Highlights
3.1.1.1. Enzyme Replacement Therapy
3.1.1.2. Stem-cell Therapy
3.1.1.3. Substrate Reduction Therapy
3.1.1.4. Others
3.2. Global Lysosomal Storage Diseases Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
3.2.1. Key Highlights
3.2.1.1. Gaucher's Disease
3.2.1.2. Fabry Disease
3.2.1.3. Pompe’s Syndrome
3.2.1.4. Mucopolysaccharidosis
3.2.1.5. Others
3.3. Global Lysosomal Storage Diseases Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
3.3.1. Key Highlights
3.3.1.1. Hospitals
3.3.1.2. Clinics
3.4. Global Lysosomal Storage Diseases Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
3.4.1. Key Highlights
3.4.1.1. North America
3.4.1.2. Europe
3.4.1.3. Asia Pacific
3.4.1.4. Latin America
3.4.1.5. Middle East & Africa
4. North America Lysosomal Storage Diseases Market Outlook, 2018 - 2031
4.1. North America Lysosomal Storage Diseases Market Outlook, by Therapy, Value (US$ Bn), 2018 - 2031
4.1.1. Key Highlights
4.1.1.1. Enzyme Replacement Therapy
4.1.1.2. Stem-cell Therapy
4.1.1.3. Substrate Reduction Therapy
4.1.1.4. Others
4.2. North America Lysosomal Storage Diseases Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
4.2.1. Key Highlights
4.2.1.1. Gaucher's Disease
4.2.1.2. Fabry Disease
4.2.1.3. Pompe’s Syndrome
4.2.1.4. Mucopolysaccharidosis
4.2.1.5. Others
4.3. North America Lysosomal Storage Diseases Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
4.3.1. Key Highlights
4.3.1.1. Hospitals
4.3.1.2. Clinics
4.3.2. BPS Analysis/Market Attractiveness Analysis
4.4. North America Lysosomal Storage Diseases Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
4.4.1. Key Highlights
4.4.1.1. U.S. Lysosomal Storage Diseases Market by Therapy, Value (US$ Bn), 2018 - 2031
4.4.1.2. U.S. Lysosomal Storage Diseases Market by Indication, Value (US$ Bn), 2018 - 2031
4.4.1.3. U.S. Lysosomal Storage Diseases Market by End User, Value (US$ Bn), 2018 - 2031
4.4.1.4. Canada Lysosomal Storage Diseases Market by Therapy, Value (US$ Bn), 2018 - 2031
4.4.1.5. Canada Lysosomal Storage Diseases Market by Indication, Value (US$ Bn), 2018 - 2031
4.4.1.6. Canada Lysosomal Storage Diseases Market by End User, Value (US$ Bn), 2018 - 2031
4.4.2. BPS Analysis/Market Attractiveness Analysis
5. Europe Lysosomal Storage Diseases Market Outlook, 2018 - 2031
5.1. Europe Lysosomal Storage Diseases Market Outlook, by Therapy, Value (US$ Bn), 2018 - 2031
5.1.1. Key Highlights
5.1.1.1. Enzyme Replacement Therapy
5.1.1.2. Stem-cell Therapy
5.1.1.3. Substrate Reduction Therapy
5.1.1.4. Others
5.2. Europe Lysosomal Storage Diseases Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
5.2.1. Key Highlights
5.2.1.1. Gaucher's Disease
5.2.1.2. Fabry Disease
5.2.1.3. Pompe’s Syndrome
5.2.1.4. Mucopolysaccharidosis
5.2.1.5. Others
5.3. Europe Lysosomal Storage Diseases Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
5.3.1. Key Highlights
5.3.1.1. Hospitals
5.3.1.2. Clinics
5.3.2. BPS Analysis/Market Attractiveness Analysis
5.4. Europe Lysosomal Storage Diseases Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
5.4.1. Key Highlights
5.4.1.1. Germany Lysosomal Storage Diseases Market by Therapy, Value (US$ Bn), 2018 - 2031
5.4.1.2. Germany Lysosomal Storage Diseases Market by Indication, Value (US$ Bn), 2018 - 2031
5.4.1.3. Germany Lysosomal Storage Diseases Market by End User, Value (US$ Bn), 2018 - 2031
5.4.1.4. U.K. Lysosomal Storage Diseases Market by Therapy, Value (US$ Bn), 2018 - 2031
5.4.1.5. U.K. Lysosomal Storage Diseases Market by Indication, Value (US$ Bn), 2018 - 2031
5.4.1.6. U.K. Lysosomal Storage Diseases Market by End User, Value (US$ Bn), 2018 - 2031
5.4.1.7. France Lysosomal Storage Diseases Market by Therapy, Value (US$ Bn), 2018 - 2031
5.4.1.8. France Lysosomal Storage Diseases Market by Indication, Value (US$ Bn), 2018 - 2031
5.4.1.9. France Lysosomal Storage Diseases Market by End User, Value (US$ Bn), 2018 - 2031
5.4.1.10. Italy Lysosomal Storage Diseases Market by Therapy, Value (US$ Bn), 2018 - 2031
5.4.1.11. Italy Lysosomal Storage Diseases Market by Indication, Value (US$Bn), 2018 - 2031
5.4.1.12. Italy Lysosomal Storage Diseases Market by End User, Value (US$Bn), 2018 - 2031
5.4.1.13. Turkey Lysosomal Storage Diseases Market by Therapy, Value (US$ Bn), 2018 - 2031
5.4.1.14. Turkey Lysosomal Storage Diseases Market by Indication, Value (US$ Bn), 2018 - 2031
5.4.1.15. Turkey Lysosomal Storage Diseases Market by End User, Value (US$ Bn), 2018 - 2031
5.4.1.16. Russia Lysosomal Storage Diseases Market by Therapy, Value (US$ Bn), 2018 - 2031
5.4.1.17. Russia Lysosomal Storage Diseases Market by Indication, Value (US$ Bn), 2018 - 2031
5.4.1.18. Russia Lysosomal Storage Diseases Market by End User, Value (US$ Bn), 2018 - 2031
5.4.1.19. Rest of Europe Lysosomal Storage Diseases Market by Therapy, Value (US$ Bn), 2018 - 2031
5.4.1.20. Rest of Europe Lysosomal Storage Diseases Market by Indication, Value (US$ Bn), 2018 - 2031
5.4.1.21. Rest of Europe Lysosomal Storage Diseases Market by End User, Value (US$ Bn), 2018 - 2031
5.4.2. BPS Analysis/Market Attractiveness Analysis
6. Asia Pacific Lysosomal Storage Diseases Market Outlook, 2018 - 2031
6.1. Asia Pacific Lysosomal Storage Diseases Market Outlook, by Therapy, Value (US$ Bn), 2018 - 2031
6.1.1. Key Highlights
6.1.1.1. Enzyme Replacement Therapy
6.1.1.2. Stem-cell Therapy
6.1.1.3. Substrate Reduction Therapy
6.1.1.4. Others
6.2. Asia Pacific Lysosomal Storage Diseases Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
6.2.1. Key Highlights
6.2.1.1. Gaucher's Disease
6.2.1.2. Fabry Disease
6.2.1.3. Pompe’s Syndrome
6.2.1.4. Mucopolysaccharidosis
6.2.1.5. Others
6.3. Asia Pacific Lysosomal Storage Diseases Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
6.3.1. Key Highlights
6.3.1.1. Hospitals
6.3.1.2. Clinics
6.3.2. BPS Analysis/Market Attractiveness Analysis
6.4. Asia Pacific Lysosomal Storage Diseases Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
6.4.1. Key Highlights
6.4.1.1. China Lysosomal Storage Diseases Market by Therapy, Value (US$ Bn), 2018 - 2031
6.4.1.2. China Lysosomal Storage Diseases Market by Indication, Value (US$ Bn), 2018 - 2031
6.4.1.3. China Lysosomal Storage Diseases Market by End User, Value (US$ Bn), 2018 - 2031
6.4.1.4. Japan Lysosomal Storage Diseases Market by Therapy, Value (US$ Bn), 2018 - 2031
6.4.1.5. Japan Lysosomal Storage Diseases Market by Indication, Value (US$ Bn), 2018 - 2031
6.4.1.6. Japan Lysosomal Storage Diseases Market by End User, Value (US$ Bn), 2018 - 2031
6.4.1.7. South Korea Lysosomal Storage Diseases Market by Therapy, Value (US$ Bn), 2018 - 2031
6.4.1.8. South Korea Lysosomal Storage Diseases Market by Indication, Value (US$ Bn), 2018 - 2031
6.4.1.9. South Korea Lysosomal Storage Diseases Market by End User, Value (US$ Bn), 2018 - 2031
6.4.1.10. India Lysosomal Storage Diseases Market by Therapy, Value (US$ Bn), 2018 - 2031
6.4.1.11. India Lysosomal Storage Diseases Market by Indication, Value (US$Bn), 2018 - 2031
6.4.1.12. India Lysosomal Storage Diseases Market by End User, Value (US$Bn), 2018 - 2031
6.4.1.13. Southeast Asia Lysosomal Storage Diseases Market by Therapy, Value (US$ Bn), 2018 - 2031
6.4.1.14. Southeast Asia Lysosomal Storage Diseases Market by Indication, Value (US$ Bn), 2018 - 2031
6.4.1.15. Southeast Asia Lysosomal Storage Diseases Market by End User, Value (US$ Bn), 2018 - 2031
6.4.1.16. Rest of Asia Pacific Lysosomal Storage Diseases Market by Therapy, Value (US$ Bn), 2018 - 2031
6.4.1.17. Rest of Asia Pacific Lysosomal Storage Diseases Market by Indication, Value (US$ Bn), 2018 - 2031
6.4.1.18. Rest of Asia Pacific Lysosomal Storage Diseases Market by End User, Value (US$ Bn), 2018 - 2031
6.4.2. BPS Analysis/Market Attractiveness Analysis
7. Latin America Lysosomal Storage Diseases Market Outlook, 2018 - 2031
7.1. Latin America Lysosomal Storage Diseases Market Outlook, by Therapy, Value (US$ Bn), 2018 - 2031
7.1.1. Key Highlights
7.1.1.1. Enzyme Replacement Therapy
7.1.1.2. Stem-cell Therapy
7.1.1.3. Substrate Reduction Therapy
7.1.1.4. Others
7.2. Latin America Lysosomal Storage Diseases Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
7.2.1. Key Highlights
7.2.1.1. Gaucher's Disease
7.2.1.2. Fabry Disease
7.2.1.3. Pompe’s Syndrome
7.2.1.4. Mucopolysaccharidosis
7.2.1.5. Others
7.3. Latin America Lysosomal Storage Diseases Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
7.3.1. Key Highlights
7.3.1.1. Hospitals
7.3.1.2. Clinics
7.3.2. BPS Analysis/Market Attractiveness Analysis
7.4. Latin America Lysosomal Storage Diseases Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
7.4.1. Key Highlights
7.4.1.1. Brazil Lysosomal Storage Diseases Market by Therapy, Value (US$ Bn), 2018 - 2031
7.4.1.2. Brazil Lysosomal Storage Diseases Market by Indication, Value (US$ Bn), 2018 - 2031
7.4.1.3. Brazil Lysosomal Storage Diseases Market by End User, Value (US$ Bn), 2018 - 2031
7.4.1.4. Mexico Lysosomal Storage Diseases Market by Therapy, Value (US$ Bn), 2018 - 2031
7.4.1.5. Mexico Lysosomal Storage Diseases Market by Indication, Value (US$ Bn), 2018 - 2031
7.4.1.6. Mexico Lysosomal Storage Diseases Market by End User, Value (US$ Bn), 2018 - 2031
7.4.1.7. Argentina Lysosomal Storage Diseases Market by Therapy, Value (US$ Bn), 2018 - 2031
7.4.1.8. Argentina Lysosomal Storage Diseases Market by Indication, Value (US$ Bn), 2018 - 2031
7.4.1.9. Argentina Lysosomal Storage Diseases Market by End User, Value (US$ Bn), 2018 - 2031
7.4.1.10. Rest of Latin America Lysosomal Storage Diseases Market by Therapy, Value (US$ Bn), 2018 - 2031
7.4.1.11. Rest of Latin America Lysosomal Storage Diseases Market by Indication, Value (US$ Bn), 2018 - 2031
7.4.1.12. Rest of Latin America Lysosomal Storage Diseases Market by End User, Value (US$ Bn), 2018 - 2031
7.4.2. BPS Analysis/Market Attractiveness Analysis
8. Middle East & Africa Lysosomal Storage Diseases Market Outlook, 2018 - 2031
8.1. Middle East & Africa Lysosomal Storage Diseases Market Outlook, by Therapy, Value (US$ Bn), 2018 - 2031
8.1.1. Key Highlights
8.1.1.1. Enzyme Replacement Therapy
8.1.1.2. Stem-cell Therapy
8.1.1.3. Substrate Reduction Therapy
8.1.1.4. Others
8.2. Middle East & Africa Lysosomal Storage Diseases Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
8.2.1. Key Highlights
8.2.1.1. Gaucher's Disease
8.2.1.2. Fabry Disease
8.2.1.3. Pompe’s Syndrome
8.2.1.4. Mucopolysaccharidosis
8.2.1.5. Others
8.3. Middle East & Africa Lysosomal Storage Diseases Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
8.3.1. Key Highlights
8.3.1.1. Hospitals
8.3.1.2. Clinics
8.3.2. BPS Analysis/Market Attractiveness Analysis
8.4. Middle East & Africa Lysosomal Storage Diseases Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
8.4.1. Key Highlights
8.4.1.1. GCC Lysosomal Storage Diseases Market by Therapy, Value (US$ Bn), 2018 - 2031
8.4.1.2. GCC Lysosomal Storage Diseases Market by Indication, Value (US$ Bn), 2018 - 2031
8.4.1.3. GCC Lysosomal Storage Diseases Market by End User, Value (US$ Bn), 2018 - 2031
8.4.1.4. South Africa Lysosomal Storage Diseases Market by Therapy, Value (US$ Bn), 2018 - 2031
8.4.1.5. South Africa Lysosomal Storage Diseases Market by Indication, Value (US$ Bn), 2018 - 2031
8.4.1.6. South Africa Lysosomal Storage Diseases Market by End User, Value(US$Bn), 2018 - 2031
8.4.1.7. Egypt Lysosomal Storage Diseases Market by Therapy, Value (US$Bn), 2018 - 2031
8.4.1.8. Egypt Lysosomal Storage Diseases Market by Indication, Value (US$ Bn), 2018 - 2031
8.4.1.9. Egypt Lysosomal Storage Diseases Market by End User, Value (US$ Bn), 2018 - 2031
8.4.1.10. Nigeria Lysosomal Storage Diseases Market by Therapy, Value (US$ Bn), 2018 - 2031
8.4.1.11. Nigeria Lysosomal Storage Diseases Market by Indication, Value (US$ Bn), 2018 - 2031
8.4.1.12. Nigeria Lysosomal Storage Diseases Market by End User, Value (US$ Bn), 2018 - 2031
8.4.1.13. Rest of Middle East & Africa Lysosomal Storage Diseases Market by Therapy, Value (US$ Bn), 2018 - 2031
8.4.1.14. Rest of Middle East & Africa Lysosomal Storage Diseases Market by Indication, Value (US$ Bn), 2018 - 2031
8.4.1.15. Rest of Middle East & Africa Lysosomal Storage Diseases Market by End User, Value (US$ Bn), 2018 - 2031
8.4.2. BPS Analysis/Market Attractiveness Analysis
9. Competitive Landscape
9.1. By Therapy vs by Indication Heat map
9.2. Company Market Share Analysis, 2023
9.3. Competitive Dashboard
9.4. Company Profiles
9.4.1. Shire PLC
9.4.1.1. Company Overview
9.4.1.2. Product Portfolio
9.4.1.3. Financial Overview
9.4.1.4. Business Strategies and Development
9.4.2. Pfizer, Inc.
9.4.2.1. Company Overview
9.4.2.2. Product Portfolio
9.4.2.3. Financial Overview
9.4.2.4. Business Strategies and Development
9.4.3. Sanofi
9.4.3.1. Company Overview
9.4.3.2. Product Portfolio
9.4.3.3. Financial Overview
9.4.3.4. Business Strategies and Development
9.4.4. BioMarin Pharmaceutical Inc.
9.4.4.1. Company Overview
9.4.4.2. Product Portfolio
9.4.4.3. Financial Overview
9.4.4.4. Business Strategies and Development
9.4.5. Actelion Ltd.
9.4.5.1. Company Overview
9.4.5.2. Product Portfolio
9.4.5.3. Financial Overview
9.4.5.4. Business Strategies and Development
9.4.6. Raptor Pharmaceutical Corp.
9.4.6.1. Company Overview
9.4.6.2. Product Portfolio
9.4.6.3. Financial Overview
9.4.6.4. Business Strategies and Development
9.4.7. Protalix Biotherapeutics Inc.
9.4.7.1. Company Overview
9.4.7.2. Product Portfolio
9.4.7.3. Financial Overview
9.4.7.4. Business Strategies and Development
9.4.8. Amicus Therapeutics, Inc.
9.4.8.1. Company Overview
9.4.8.2. Product Portfolio
9.4.8.3. Financial Overview
9.4.8.4. Business Strategies and Development
10. Appendix
10.1.Research Methodology
10.2.Report Assumptions 10.3.Acronyms and Abbreviations

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Shire PLC
  • Pfizer, Inc.
  • Sanofi
  • BioMarin Pharmaceutical Inc.
  • Actelion Ltd.
  • Raptor Pharmaceutical Corp.
  • Protalix Biotherapeutics Inc.
  • Amicus Therapeutics, Inc.

Methodology

Loading
LOADING...

Related Topics

Related Reports

Lysosomal Storage Diseases Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 - Product Image

Lysosomal Storage Diseases Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028

  • Report
  • 189 Pages
  • Global
From
Global Lysosomal Storage Diseases Market by Disease Type (Fabry Diseases, Gaucher's Diseases, Mucopolysaccharidosis), Type of Therapy (Enzyme Replacement Therapy, Stem Cell Therapy, Substrate Reduction Therapy), End User - Forecast 2024-2030 - Product Image

Global Lysosomal Storage Diseases Market by Disease Type (Fabry Diseases, Gaucher's Diseases, Mucopolysaccharidosis), Type of Therapy (Enzyme Replacement Therapy, Stem Cell Therapy, Substrate Reduction Therapy), End User - Forecast 2024-2030

  • Report
  • 181 Pages
  • Global
From
Lysosomal Disease Treatment Global Market Report 2024 - Product Image

Lysosomal Disease Treatment Global Market Report 2024

  • Report
  • 200 Pages
  • Global
From
Lysosomal Storage Diseases - Global Strategic Business Report - Product Image

Lysosomal Storage Diseases - Global Strategic Business Report

  • Report
  • 193 Pages
  • Global
From
Lysosomal Storage Diseases Therapeutics Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

Lysosomal Storage Diseases Therapeutics Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 94 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.